Dr. Doru Paul, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 33
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 117
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
NY license 216174
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- New York-Presbyterian Hospital New York, NY
Medical groups
- Weill Medical College of Cornell (2,051 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 117
- Services billed
- 2,385
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, paclitaxel, 1 mg | 3,843 | 15 |
| Injection, aprepitant, 1 mg | 2,990 | 11 |
| Injection, palonosetron hcl, 25 mcg | 821 | 36 |
| Injection, dexamethasone sodium phosphate, 1 mg | 453 | 28 |
| Established patient office or other outpatient visit, 30-39 minutes | 252 | 75 |
| Injection of additional new drug or substance into vein | 188 | 41 |
| Injection, carboplatin, 50 mg | 170 | 16 |
| Administration of chemotherapy into vein, 1 hour or less | 152 | 51 |
| Injection, fluorouracil, 500 mg | 97 | 15 |
| Administration of additional new drug or substance into vein, 1 hour or less | 80 | 34 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 11 companies reported 16 payments worth $421 in total to this clinician.
| Astellas Pharma US Inc | $62.90 |
|---|---|
| Novartis Pharmaceuticals Corporation | $55.02 |
| Lilly USA, LLC | $53.86 |
| Incyte Corporation | $49.92 |
| Merck Sharp & Dohme LLC | $41.35 |
| Beone Medicines USA, Inc. | $31.34 |
| Rigel Pharmaceuticals, Inc. | $30.80 |
| Daiichi Sankyo Inc. | $29.30 |
| Food and Beverage | $367 |
|---|---|
| Education | $53.86 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Lilly USA, LLC Aug 26, 2025 | Education in-kind | $53.86 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $16,671 in research payments for these studies, mostly to the institutions running them.
- Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors
Beone Medicines USA, Inc. · Completed · NCT03744468 - A Phase 3 Clinical Trial of Pembrolizumab MK-3475 in First Line Treatment of Recurrent,Metastatic Head and Neck Squamous Cell Carcinoma
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.